fda glp-1 restriction

fda glp-1 restriction

5 Warning Signals Prescription Weight Loss?

There are five key warning signals that indicate potential problems with prescription weight-loss therapies. I outline each signal, why it matters, and how recent FDA actions could reshape the market. The FDA’s early-2024 decision removed three GLP-1 products - semaglutide, tirzepatide and liraglutide - from the 503B bulk submission